WebApr 3, 2024 · Hayley Virgil. In addition to granting fast track designation to RRx-001, the FDA accepts an investigational new drug application for the agent to reduce and/or prevent radiation- and chemotherapy-associated oral mucositis. ... (NCT03515538) as a preventative measure against oral mucositis in patients with head and neck cancer undergoing ... WebView Hayley Virgil’s profile on LinkedIn, the world’s largest professional community. ... Assistant Managing Editor at Cancer Network …
FDA Grants ODD to Investigational Oral CDK9 Inhibitor for Ewing …
WebHayley Virgil. Assistant Editor. Russ Conroy. Ariana Pelosci. Nicholas Wrigley. Business. President & CEO. Mike Hennessy Jr. Senior Vice President, Content. Silas Inman. Executive Vice President. Brian Haug. 609-325-4780 • [email protected]. Director of Sales. Michelle Janin. 732-429-4316 • [email protected]. Associate Director of … WebFeb 14, 2024 · The National Comprehensive Cancer Network (NCCN) has updated clinical practice guidelines for Adolescent and Young Adults (AYA) Oncology to include sodium thiosulfate injection (Pedmark) to aid in mitigating the risk of cisplatin-associated ototoxicity in pediatric patients with localized, non-metastatic solid malignancies. 1 “Patients have … ibis city centre bristol
FDA Approves TLX591-CDx Prostate Cancer Imaging ... - Cancer Network
WebJan 9, 2024 · Hayley Virgil. The overall survival improvements were observed when tumor-treating fields were combined with immune checkpoint inhibitors with a positive trend towards improvement when combined with docetaxel in those with stage IV non–small cell lung cancer. ... (OS) compared with standard therapies alone in patients with stage IV … WebFeb 2, 2024 · Hayley Virgil February 2, 2024 - ASCO has chosen molecular profiling driving progress in gastointestinal cancers as its Advance of the Year. Howard A. “Skip” Burris, III, MD, FACP, FASCO WebSep 17, 2024 · September 17, 2024. Hayley Virgil. Findings from the phase 3 COSMIC-311 trial led to the approval of cabozantinib in patients with radioactive iodine–refractory locally advanced or metastatic differentiated thyroid cancer. Cabozantinib (Cabometyx) has been approved by the FDA for adult and pediatric patients aged 12 years or older with ... ibis city berlin west